Altimmune Profit Margin

The latest profit margin for ALT is -296000.0% as of June 2026. That compares with -438730.0% in the prior-year period — up 32.5% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside Altimmune's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALT's profit margin moved from -438730.0% to -296000.0% — a 32.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Altimmune's valuation or profitability profile.

Against Healthcare companies, ALT currently prints -296000.0% for profit margin, while the sector average sits near 13.71%. That is roughly 2158975.1% below the sector mean. Large gaps often invite a closer look at Altimmune's growth, margins, and balance sheet.

Profit Margin shows how effectively Altimmune converts resources into returns. At -296000.0%, ALT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -438730.0% in the prior-year period — up 32.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALT's profit margin (-296000.0%), review year-over-year change from -438730.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.